(Reuters) - A major trial of Merck & Co Inc's Tredaptive medicine to increase "good" HDL cholesterol has raised safety concerns and showed it was no better at preventing heart attacks, deaths or strokes than traditional statin drugs that lower "bad" LDL cholesterol, the company said on Thursday. Merck said the experimental medicine had significantly raised the incidence of some types of nonfatal but serious side effects in the study, which followed more than 25,000 patients for almost four years. Merck shares fell 2.5 percent to $42. ...
via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment